Jones Erika 4

What Happened

• Erika Jones, Senior Vice President, Finance and Corporate Controller of Black Diamond Therapeutics (BDTX), received an award on Jan 21, 2026 for 200,000 derivative shares (reported as acquired at $0.00). This filing reports a grant/option award rather than an open-market purchase or sale.

Key Details

• Transaction date: January 21, 2026; Form 4 filed January 23, 2026.
• Transaction type/code: Award/Grant (derivative) — 200,000 shares @ $0.00.
• Vesting: 25% vests and becomes exercisable on January 21, 2027; remaining shares vest in 36 equal monthly installments thereafter, subject to continued service (per footnote).
• Shares owned after transaction: Not disclosed in the filing.
• No immediate exercise or sale reported; this is a grant of an equity award, not a cash transaction.

Context

• This is a standard equity award to an executive as part of compensation. It does not represent a purchase or sale of existing shares and does not by itself indicate buying or selling sentiment.
• Vesting schedule means the award will only become exercisable over time if the reporting person remains employed.